According to Bloomberg, AI+Drug Delivery and Drug Discovery CompaniesMETiS TechBioConsider conducting in Hong KongIPO, raising approximately2Billion US dollars。The company is working with advisors to arrange, informed sources said.IPOIt is appropriate and may be carried out before the end of this year.People familiar with the matter said that relevant discussions are still ongoing.IPODetails such as scale and timing may change. METiS TechBio did not respond to the message.METiS TechBio was founded in 2020 and incubated by XtalPi.MIT scientist Cai-Da Lai,Dr. Wang Wen-Shou, andHongmin Chen, Academician of the National Academy of Engineering (USA)Co-founded.The CEO, Lai Caida, is a Ph.D. in Chemical Engineering from MIT. During his Ph.D., he worked as a researcher at the Novartis-MIT Center, focusing on drug polymorph process research using computational models and big data.METiS TechBio is one of the few companies globally that focuses on AI + drug delivery. Based on AI technology, METiS TechBio has developedWorld's First METiSLipidLM Lipid Language Model and PhatGPT Lipid Generation Model, which can quickly generate lipids,It has been experimentally validated in liver, lung, and muscle-specific targeting LNPs.METiS TechBio Has Independently Developed Three Major AI+ Core Technology Platforms:
AI-Driven Nucleic Acid Delivery System Design Platform (AiLNP)：An independently developed library of tens of thousands of cationic lipids and an LNP delivery system with independent intellectual property rights, with expression efficiency surpassing industry standards by more than ten times.
AI-Driven mRNA Sequence Design Platform (AiRNA):Utilizing quantum chemistry and machine learning algorithms, combined with the biological and physicochemical properties of nucleic acids, to scale up the design of the full-length mRNA sequence space, establishing an mRNA synthesis and purification platform for rapid mRNA production.
AI-Driven Small Molecule Formulation Design Platform (AiTEM):The large-scale design of formulation prescriptions can generate tens of thousands of prescriptions per week and obtain the optimal prescription solution within a month.
METiS TechBio has builtMore Than a Dozen Product R&D Pipelines，IncludingRNA drugs and small molecule new drugs for the treatment of serious diseases such as cancer, cardiovascular and cerebrovascular diseases, Alzheimer's disease, and ALS.
As of now,The Company's FirstNew Drug Product MTS004 Orally Disintegrating TabletsCompleted Phase III clinical trials, advanced multiple projects to the clinical stage, and initiated the first mRNA pipeline into human trials.
To date, METiS TechBio has completed multiple rounds of financing, accumulating nearly 300 million US dollars in funding.In March 2020, received millionsMETiS TechBio completed its angel round of financing in US dollars, led by Frees Fund, followed by Source Code Capital, and strategically followed by XtalPi;In December 2020, METiS TechBio completed angel+ and Pre-A rounds of financing worth over 100 million yuan, with investments from Sequoia Capital, Frees Fund, Source Code Capital, XtalPi, Lightspeed Venture Partners, and 5Y Capital.In April 2022, completed two rounds of financing totaling 150 million US dollars, led by PICC Capital and China Life Equity, with Sequoia China, FiveSource Capital, CMB International, Lightspeed China, Monolith, and Frees Fund following;June 2024,Completed $100 Million Series C Financing, led by a fund under CICC Capital, with Taiping Hong Kong Insurance Technology Innovation Fund following up.
'%20fill='%23FFFFFF'%3E%3Crect%20x='249'%20y='126'%20width='1'%20height='1'%3E%3C/rect%3E%3C/g%3E%3C/g%3E%3C/svg%3E)